Javier Chaparro‐Riggers

Author

Also Known As

J Chaparro-Riggers, J. Chaparro-Riggers, J.F. Chaparro-Riggers, Javier Chaparro-Riggers, Javier Chaparro-riggers, Javier Chaparro‐Riggers, Javier F Chaparro-Riggers, Javier F. Chaparro-Riggers, Javier F. Chaparro‐Riggers, Javier F. Chaparro‐Riggers

137

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Allogene Therapeutics (United States)Bristol-Myers Squibb (Germany)Cellectis (United States)Georgia Institute of Technology

About

Javier Chaparro‐Riggers is an author at Pfizer (United States) specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	1.2K
2	Natural Sciences	6	6	623
3	Engineering	4	4	372
4	Biochemistry	4	4	372
5	Allergy	1	1	145

Javier Chaparro‐Riggers

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates Pavel Strop, Shu‐Hui Liu, Magdalena Dorywalska, Chemistry & Biology Location MattersDrug TargetingMedicineImmunologyAntibody Screening	2013	486
Human Responses to Influenza Vaccination Show Seroconversion Signatures and Convergent Antibody Rearrangements Katherine Jackson, Yi Liu, Krishna M. Roskin, Cell Host & Microbe VaccinationConvergent Antibody RearrangementsVaccine TargetImmunologyVirology	2014	254
Fabs Enable Single Particle cryoEM Studies of Small Proteins Shenping Wu, Agustin Avila-Sakar, Jung‐Min Kim, Structure Natural SciencesSingle Particle BiophysicsMolecular BiologyProtein RefoldingProteomics	2012	185
The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity Yasmina Abdiche, Yik A. Yeung, Javier Chaparro‐Riggers, mAbs ImmunologyImmune RegulationInnate ImmunityImmune SystemImmunotherapy	2015	183
Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9 Javier Chaparro‐Riggers, Liang Hong, Rachel M. DeVay, Journal of Biological Chemistry	2012	164
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma Cesar Sommer, Bijan Boldajipour, Tracy C. Kuo, Molecular Therapy	2019	156
Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair Pavel Strop, Wei-Hsien Ho, Leila M. Boustany, Journal of Molecular Biology Immunocytochemical TechniqueAllergyHuman Leukocyte AntigenAutoimmune DiseaseIgg2 Antibodies	2012	145
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab Sherman M. Chin, Christopher R. Kimberlin, Zygy Roe-Žurž, Nature Communications	2018	143
Development of a Thermostable Glucose Dehydrogenase by a Structure‐Guided Consensus Concept Eduardo Vázquez‐Figueroa, Javier Chaparro‐Riggers, Andreas S. Bommarius ChemBioChem Bioorganic ChemistryEngineeringAldo-keto ReductaseWild-type GdhMolecular Biology	2007	134
Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity Shih-Hsun Chen, Pawel K. Dominik, Jessica Stanfield, Journal for ImmunoTherapy of Cancer	2021	133

Page 1